Welcome to our dedicated page for Petvivo Holdings SEC filings (Ticker: PETVW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
PetVivo Holdings, Inc. (PETVW) filings document material events for a veterinary biomedical device company operating through PetVivo Animal Health and PetVivo AI. Recent Form 8-K disclosures cover material definitive agreements, unregistered sales of equity securities, subscription-agreement financing, and capital-structure changes involving restricted common stock.
The company’s filings also record governance changes, including director resignations and board-size reductions, along with Regulation FD investor-presentation materials. These disclosures frame PetVivo’s public-company reporting around financing activity, board composition, subsidiary operations, veterinary medical products and investor communications.
PetVivo Holdings, Inc. (PETV) furnished an investor presentation as Exhibit 99.1 via an 8‑K. The Company states representatives may use this presentation at investor conferences and other forums, and it may also appear on the corporate website.
The information is provided under Regulation FD, Item 7.01, is furnished and not deemed filed under Section 18 of the Exchange Act, and is not incorporated by reference into other filings except as specifically referenced. The exhibit is titled “PetVivo Holdings, Inc. Investor Presentation” and is dated November 2025.
PetVivo Holdings, Inc. (PETV) furnished an investor presentation as Exhibit 99.1 via an 8‑K. The Company states representatives may use this presentation at investor conferences and other forums, and it may also appear on the corporate website.
The information is provided under Regulation FD, Item 7.01, is furnished and not deemed filed under Section 18 of the Exchange Act, and is not incorporated by reference into other filings except as specifically referenced. The exhibit is titled “PetVivo Holdings, Inc. Investor Presentation” and is dated November 2025.
A.L. Sarroff Fund, LLC filed Amendment No. 10 to Schedule 13G reporting beneficial ownership of 8,846,288 shares of PetVivo Holdings, Inc. common stock, representing 31.7% of the class. The filer reports sole voting and sole dispositive power over the same 8,846,288 shares, with no shared power.
The filing states reliance on Rule 13d-1(c) and certifies the securities were not acquired to change or influence control. It also discloses 4,780,008 warrants with specified future exercisability dates that are not included in the Schedule 13G ownership per Rule 13d-3(d)(1). As context, the issuer had 27,903,361 shares outstanding as of August 14, 2025, and the filer notes its holdings were 26.5% as of June 30, 2025.
A.L. Sarroff Fund, LLC filed Amendment No. 10 to Schedule 13G reporting beneficial ownership of 8,846,288 shares of PetVivo Holdings, Inc. common stock, representing 31.7% of the class. The filer reports sole voting and sole dispositive power over the same 8,846,288 shares, with no shared power.
The filing states reliance on Rule 13d-1(c) and certifies the securities were not acquired to change or influence control. It also discloses 4,780,008 warrants with specified future exercisability dates that are not included in the Schedule 13G ownership per Rule 13d-3(d)(1). As context, the issuer had 27,903,361 shares outstanding as of August 14, 2025, and the filer notes its holdings were 26.5% as of June 30, 2025.
PetVivo Holdings (PETV) expanded its Board to eight directors and appointed Josh Ruben, effective October 28, 2025. Ruben, age 39, was deemed “independent” under Exchange Act rules and will serve until the next annual meeting and until a successor is elected and qualified.
Ruben is Managing Director of Life Sciences at Trinity Capital and previously led Life Science Tools and Diagnostics coverage at RBC Capital Markets after nine years at Wells Fargo Securities. His compensation will align with the Company’s non-employee director program on a pro‑rated basis. He has no disclosed related-party transactions or family relationships with current directors or officers and has not yet been appointed to any committees.
PetVivo Holdings (PETV) expanded its Board to eight directors and appointed Josh Ruben, effective October 28, 2025. Ruben, age 39, was deemed “independent” under Exchange Act rules and will serve until the next annual meeting and until a successor is elected and qualified.
Ruben is Managing Director of Life Sciences at Trinity Capital and previously led Life Science Tools and Diagnostics coverage at RBC Capital Markets after nine years at Wells Fargo Securities. His compensation will align with the Company’s non-employee director program on a pro‑rated basis. He has no disclosed related-party transactions or family relationships with current directors or officers and has not yet been appointed to any committees.
PetVivo Holdings (PETV) reported an insider transaction on Form 4. Chief Financial Officer Garry Lowenthal received 75,000 shares of restricted common stock on 10/23/2025 at a reported price of $1.27 per share. The grant was issued to a corporation owned by him as compensation for past performance. After this grant, he beneficially owns 667,967 shares, held indirectly through the corporation.
PetVivo Holdings (PETV) reported an insider transaction on Form 4. Chief Financial Officer Garry Lowenthal received 75,000 shares of restricted common stock on 10/23/2025 at a reported price of $1.27 per share. The grant was issued to a corporation owned by him as compensation for past performance. After this grant, he beneficially owns 667,967 shares, held indirectly through the corporation.
PetVivo Holdings (PETV) reported an insider transaction on a Form 4. CEO and Director John Lai acquired 75,000 shares of common stock on 10/23/2025 at $1.27 per share. The filing states the shares were a grant of restricted common stock to a corporation he owns, as compensation for past performance by converting a past accrued bonus into common stock.
After the transaction, Lai beneficially owned 2,095,710 shares, held indirectly through the corporation.
PetVivo Holdings (PETV) reported an insider transaction on a Form 4. CEO and Director John Lai acquired 75,000 shares of common stock on 10/23/2025 at $1.27 per share. The filing states the shares were a grant of restricted common stock to a corporation he owns, as compensation for past performance by converting a past accrued bonus into common stock.
After the transaction, Lai beneficially owned 2,095,710 shares, held indirectly through the corporation.
PetVivo Holdings (PETV) reported an insider equity award. Director Diane Levitan acquired 12,500 shares of restricted common stock at $1.28 on 10/10/2025. The award is part of an aggregate annual grant of 50,000 shares for Board service, vesting in four equal installments of 12,500 at the beginning of each quarter.
Following this transaction, Levitan beneficially owns 56,489 shares, held directly.
PetVivo Holdings (PETV) reported an insider equity award. Director Diane Levitan acquired 12,500 shares of restricted common stock at $1.28 on 10/10/2025. The award is part of an aggregate annual grant of 50,000 shares for Board service, vesting in four equal installments of 12,500 at the beginning of each quarter.
Following this transaction, Levitan beneficially owns 56,489 shares, held directly.
PetVivo Holdings (PETV) director reported multiple stock grants. On 10/01/2025, the director acquired 14,935 shares of restricted common stock at $1.19 as compensation for prior consulting services. On 10/10/2025, additional restricted stock grants were recorded: 12,500 shares at $1.28 for quarterly Board service vesting, 50,000 shares at $1.28 tied to a warrant exercise with a $25,000 payment to the company, and 100,000 shares at $1.28 tied to a warrant exercise with a $50,000 payment to the company. Following these transactions, beneficial ownership stood at 311,807 shares, held directly.
PetVivo Holdings (PETV) director reported multiple stock grants. On 10/01/2025, the director acquired 14,935 shares of restricted common stock at $1.19 as compensation for prior consulting services. On 10/10/2025, additional restricted stock grants were recorded: 12,500 shares at $1.28 for quarterly Board service vesting, 50,000 shares at $1.28 tied to a warrant exercise with a $25,000 payment to the company, and 100,000 shares at $1.28 tied to a warrant exercise with a $50,000 payment to the company. Following these transactions, beneficial ownership stood at 311,807 shares, held directly.
PetVivo Holdings (PETV) reported a Form 4 for director Robert Rudelius. On 10/10/2025, he acquired 12,500 shares of common stock at $1.28 as part of an annual 50,000 restricted-share board compensation grant that vests in four equal quarterly installments. Following the transaction, he beneficially owned 314,369 shares directly and 21,000 shares indirectly via a corporation.
PetVivo Holdings (PETV) reported a Form 4 for director Robert Rudelius. On 10/10/2025, he acquired 12,500 shares of common stock at $1.28 as part of an annual 50,000 restricted-share board compensation grant that vests in four equal quarterly installments. Following the transaction, he beneficially owned 314,369 shares directly and 21,000 shares indirectly via a corporation.
PetVivo Holdings (PETV) reported a Form 4 showing Director Joseph Jasper acquired 12,500 restricted common shares at $1.28 on 10/10/2025. The transaction reflects the first quarterly vesting from an annual board compensation grant of 50,000 shares, vesting in four equal installments of 12,500 each.
Following the transaction, Jasper beneficially owned 100,159 shares directly, plus 2,000 shares indirectly held by his spouse.
PetVivo Holdings (PETV) reported a Form 4 showing Director Joseph Jasper acquired 12,500 restricted common shares at $1.28 on 10/10/2025. The transaction reflects the first quarterly vesting from an annual board compensation grant of 50,000 shares, vesting in four equal installments of 12,500 each.
Following the transaction, Jasper beneficially owned 100,159 shares directly, plus 2,000 shares indirectly held by his spouse.
PetVivo Holdings (PETV) disclosed a Form 4 for a director on 10/10/2025, reporting the acquisition of 12,500 shares of common stock at $1.28 per share. Following the transaction, the director beneficially owns 73,661 shares directly.
The filing notes this is part of an aggregate annual grant of 50,000 restricted shares for Board service, vesting in four equal installments of 12,500 shares at the beginning of each quarter.
PetVivo Holdings (PETV) disclosed a Form 4 for a director on 10/10/2025, reporting the acquisition of 12,500 shares of common stock at $1.28 per share. Following the transaction, the director beneficially owns 73,661 shares directly.
The filing notes this is part of an aggregate annual grant of 50,000 restricted shares for Board service, vesting in four equal installments of 12,500 shares at the beginning of each quarter.